IBS-C薬のアジア太平洋市場2020-2077

◆英語タイトル:ASIA PACIFIC IBS-C DRUG MARKET FORECAST 2020-2028
◆商品コード:INK20MY128
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年2月
◆ページ数:143
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGS The IBS-C drug market of Asia Pacific is estimated to reach a CAGR of 9.96% over the forecast period, 2020-2028. With the increase in population, there is also an increase in government expenditure in the healthcare sector. The economic growth in the region is also increasing the ability of the people to spend more on medications and healthcare services. These factors are creating huge potential for the market.

MARKET INSIGHTS
The Asia Pacific IBS-C drug market growth is further analyzed by segmenting the region into South Korea, Japan, Thailand, Australia & New Zealand, China, Indonesia, India, Vietnam, and the rest of Asia Pacific. Indonesia’s healthcare industry is growing rapidly as a result of increasing government expenditure and growing life expectancy. The pharmaceutical market value of the country is gearing up. There is strong growth of manufacturers of generic drugs in Indonesia, and several domestic players are actively leading the industry. In countries like Thailand, the healthcare industry is one of the fastest-growing sectors. There is a 3.51% increase in the healthcare sector in 2016 as compared to 2015. Thailand imported 65% of its pharmaceuticals from Europe, the US, and Canada. In Australia, one out of five people experience symptoms of IBS at some point of time in their lifetime and is twice as common in women as in men. However, it can be treated, and it is among the most common complaints presenting to GPs affecting around 9% of Australians. In the region of the rest of Asia Pacific, the geriatric population is growing at a rapid pace leading to chronic diseases and age-related surgeries. The healthcare investments by the private sector are growing tremendously. Medical tourism is identified to play a vital role in boosting growth and investment in the market.

COMPETITIVE INSIGHTS
Abbott Laboratories, Astellas Pharma US, Inc., Yuhan Corp., Novartis, etc. are some of the renowned companies operating in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
3.2.2. IBS CAN BE A HERITABILITY ISSUE
3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. STRICT FDA REGULATIONS
3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK
5. MARKET BY PRESCRIPTION TYPE
5.1. PRESCRIBED
5.1.1. BRANDED
5.1.2. GENERIC
5.2. OVER THE COUNTER
6. MARKET BY DRUG TYPE
6.1. LUBIPROSTONE
6.2. LINACLOTIDE
6.3. STIMULANT LAXATIVES
6.3.1. BISACODYL
6.3.2. SENNA
6.4. OSMOTIC LAXATIVES
6.4.1. LACTULOSE
6.4.2. POLYETHYLENE GLYCOL
6.5. OTHER DRUG TYPES
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. CHINA
7.1.2. JAPAN
7.1.3. INDIA
7.1.4. SOUTH KOREA
7.1.5. INDONESIA
7.1.6. THAILAND
7.1.7. VIETNAM
7.1.8. AUSTRALIA & NEW ZEALAND
7.1.9. REST OF ASIA PACIFIC
8. COMPANY PROFILES
8.1. CATALENT PHARMACEUTICALS SOLUTIONS
8.2. ABBOTT LABORATORIES
8.3. NOVARTIS PHARMA AG
8.4. ASTELLAS PHARMACEUTICALS
8.5. ARDELYX, INC.
8.6. SYNTHETIC BIOLOGICS, INC.
8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.8. BAMA-GEVE, SLU
8.9. FERRING BV
8.10. IRONWOOD PHARMACEUTICALS, INC.
8.11. SALIX PHARMACEUTICALS LTD.
8.12. NORGINE B.V.
8.13. PROMETHEUS LABORATORIES, INC.
8.14. ALBIREO PHARMA, INC.
8.15. YUHAN CORP.
8.16. ASTRAZENECA PLC
8.17. THE MENARINI GROUP
8.18. ONO PHARMACEUTICAL CO. LTD.
8.19. ACTAVIS NORDIC A/S

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IBS-C DRUG
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 5: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8: ASIA PACIFIC IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: ASIA PACIFIC IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)
TABLE 11: PRODUCT PROFILE (LINACLOTIDE)
TABLE 12: ASIA PACIFIC IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: ASIA PACIFIC IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: PRODUCT PROFILE (BISACODYL)
TABLE 15: PRODUCT PROFILE (SENNA)
TABLE 16: ASIA PACIFIC IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: ASIA PACIFIC IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: PRODUCT PROFILE (LACTULOSE)
TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 20: PRODUCT PROFILE (PSYLLIUM)
TABLE 21: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: ASIA PACIFIC IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
FIGURE 7: ASIA PACIFIC IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
FIGURE 12: ASIA PACIFIC IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
FIGURE 20: ASIA PACIFIC IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 22: CHINA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: CHINESE MEDICINE TCM TREATMENT FOR IBS
FIGURE 24: JAPAN IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 25: INDIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 26: SOUTH KOREA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 27: INDONESIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 28: THAILAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 29: VIETNAM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 30: AUSTRALIA & NEW ZEALAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 31: REST OF ASIA PACIFIC IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[IBS-C薬のアジア太平洋市場2020-2077]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆